151 related articles for article (PubMed ID: 37366909)
1. Associations of Clinical and Dosimetric Parameters with Urinary Toxicities after Prostate Brachytherapy: A Long-Term Single-Institution Experience.
Ito M; Makita C; Mori T; Takano H; Kumano T; Matsuo M; Iinuma K; Kawase M; Nakane K; Nakano M; Koie T
Curr Oncol; 2023 Jun; 30(6):5680-5689. PubMed ID: 37366909
[TBL] [Abstract][Full Text] [Related]
2. Assessment of lower urinary symptom flare with overactive bladder symptom score and International Prostate Symptom Score in patients treated with iodine-125 implant brachytherapy: long-term follow-up experience at a single institute.
Miyake M; Tanaka N; Asakawa I; Hori S; Morizawa Y; Tatsumi Y; Nakai Y; Inoue T; Anai S; Torimoto K; Aoki K; Hasegawa M; Fujii T; Konishi N; Fujimoto K
BMC Urol; 2017 Aug; 17(1):62. PubMed ID: 28806948
[TBL] [Abstract][Full Text] [Related]
3. Assessment of Long-term Changes in Lower Urinary Tract Symptoms in Patients With Prostate Cancer Who Underwent Low-dose-rate Prostate Brachytherapy.
Iinuma K; Nakano M; Kato T; Kato D; Takai M; Maekawa YM; Nakane K; Mizutani K; Tsuchiya T; Ishihara T; Ito M; Matsuo M; Koie T
Urology; 2020 Aug; 142():213-220. PubMed ID: 32416115
[TBL] [Abstract][Full Text] [Related]
4. Chronological Changes of Lower Urinary Tract Symptoms in Elderly Patients with Prostate Cancer after Low-Dose-Rate Prostate Brachytherapy.
Tsuchiya K; Kawase M; Nakane K; Nakano M; Iinuma K; Kato D; Takai M; Tobisawa Y; Mori T; Takano H; Kumano T; Matsuo M; Ito T; Koie T
Life (Basel); 2023 Jul; 13(7):. PubMed ID: 37511882
[TBL] [Abstract][Full Text] [Related]
5. Chronological changes of lower urinary tract symptoms after low-dose-rate brachytherapy for prostate cancer using SpaceOAR® system.
Taniguchi T; Iinuma K; Nakano M; Kawase M; Takeuchi S; Kato D; Takai M; Nakane K; Ishihara T; Ito M; Kumano T; Matsuo M; Koie T
Prostate Int; 2022 Dec; 10(4):207-212. PubMed ID: 36570644
[TBL] [Abstract][Full Text] [Related]
6. Modified transurethral resection of the prostate (TURP) for men with moderate lower urinary tract symptoms (LUTS) before brachytherapy is safe and feasible.
Brousil P; Hussain M; Lynch M; Laing RW; Langley SE
BJU Int; 2015 Apr; 115(4):580-6. PubMed ID: 24802744
[TBL] [Abstract][Full Text] [Related]
7. Patient assessment of lower urinary tract symptoms using the international prostate symptom score following low-dose-rate prostate brachytherapy.
Farris JC; Hughes RT; Steber CR; Craven TE; Frizzell BA
Brachytherapy; 2021; 20(6):1107-1113. PubMed ID: 34353749
[TBL] [Abstract][Full Text] [Related]
8. Factors affecting urinary frequency after low-dose-rate brachytherapy for prostate cancer.
Uematsu T; Torimoto K; Tanaka N; Asakawa I; Hori S; Yamaki K; Nakai Y; Miyake M; Anai S; Hasegawa M; Fujimoto K
Low Urin Tract Symptoms; 2022 Jan; 14(1):4-9. PubMed ID: 34288506
[TBL] [Abstract][Full Text] [Related]
9. Comparison of chronological changes in urinary function in patients who underwent low-dose-rate brachytherapy for prostate cancer-A randomized controlled trial of alpha-1 adrenoceptor antagonist alone versus combination with cyclooxygenase-2 inhibitor.
Tanaka N; Torimoto K; Asakawa I; Miyake M; Anai S; Nakai Y; Fujii T; Hasegawa M; Fujimoto K
Brachytherapy; 2018; 17(3):537-543. PubMed ID: 29402711
[TBL] [Abstract][Full Text] [Related]
10. Impact of serum 25-OH vitamin D level on lower urinary tract symptoms in men: a step towards reducing overactive bladder.
Yoo S; Oh S; Kim HS; Choi HS; Park J; Cho SY; Son H; Jeong H; Lee HW; Cho MC
BJU Int; 2018 Oct; 122(4):667-672. PubMed ID: 29745000
[TBL] [Abstract][Full Text] [Related]
11. Changes in lower urinary tract symptoms after iodine-125 brachytherapy for prostate cancer.
Onishi K; Tanaka N; Miyake M; Nakai Y; Anai S; Torimoto K; Yamaki K; Asakawa I; Hasegawa M; Fujii T; Konishi N; Fujimoto K
Clin Transl Radiat Oncol; 2019 Jan; 14():51-58. PubMed ID: 30547097
[TBL] [Abstract][Full Text] [Related]
12. The role of intravesical prostatic protrusion in the evaluation of overactive bladder in male patients with LUTS.
Tsai CH; Lee WC; Shen YC; Wang HJ; Chuang YC
Int Urol Nephrol; 2020 May; 52(5):815-820. PubMed ID: 31897874
[TBL] [Abstract][Full Text] [Related]
13. International Prostate Symptom Score for assessing lower urinary tract dysfunction in women.
Hsiao SM; Lin HH; Kuo HC
Int Urogynecol J; 2013 Feb; 24(2):263-7. PubMed ID: 22588143
[TBL] [Abstract][Full Text] [Related]
14. Decline in acute urinary toxicities with increased institutional experience: 15-year experience of permanent seed prostate brachytherapy in a single Australasian institution.
Ong WL; Matheson B; Millar J
Brachytherapy; 2017; 16(2):313-322. PubMed ID: 28017293
[TBL] [Abstract][Full Text] [Related]
15. Quantitative analysis of genitourinary toxicity after iodine-125 brachytherapy for localized prostate cancer: Followup of the International Prostate Symptom Score and Overactive Bladder Symptom Score.
Sakayori M; Ohashi T; Momma T; Kaneda T; Nishimura S; Sutani S; Yamashita S; Shigematsu N
Brachytherapy; 2017; 16(4):806-814. PubMed ID: 28552494
[TBL] [Abstract][Full Text] [Related]
16. Useful parameters to predict the presence of detrusor overactivity in male patients with lower urinary tract symptoms.
Matsukawa Y; Majima T; Ishida S; Funahashi Y; Kato M; Gotoh M
Neurourol Urodyn; 2020 Jun; 39(5):1394-1400. PubMed ID: 32259358
[TBL] [Abstract][Full Text] [Related]
17. Urinary symptom flare following I-125 prostate brachytherapy.
Cesaretti JA; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):1085-92. PubMed ID: 12829146
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Factors for Resolution Delay of Lower Urinary Tract Symptoms in Patients with Prostate Cancer after Low-Dose-Rate Brachytherapy.
Taniguchi T; Kawase M; Nakane K; Nakano M; Iinuma K; Kato D; Takai M; Tobisawa Y; Mori T; Takano H; Kumano T; Matsuo M; Ito T; Koie T
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627078
[TBL] [Abstract][Full Text] [Related]
19. Comparison of patient-reported acute urinary and sexual toxicity scores in a 6- versus 2-fraction course of high-dose-rate prostate brachytherapy monotherapy.
Ragab O; Banerjee R; Park SJ; Patel S; Zhang M; Wang J; Velez M; Demanes DJ; Kamrava M
J Med Imaging Radiat Oncol; 2018 Feb; 62(1):109-115. PubMed ID: 28856847
[TBL] [Abstract][Full Text] [Related]
20. Permanent prostate brachytherapy is safe in men with severe baseline lower urinary tract symptoms.
Winoker JS; Say RK; Mehrazin R; Stock RG; Stone NN
Brachytherapy; 2019; 18(3):332-337. PubMed ID: 30890317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
